Israeli cardiac cath lab technology developer Corindus has opened a U.S. headquarters in Auburndale, MA. The facility will manage sales, marketing, and clinical affairs in the U.S., according to the Haifa-based firm.
Corindus was originally established in 2002 as NaviCath, and has developed CorPath, a catheter manipulation system to advance and torque coronary guidewires and stent systems in a patient's artery from a remote location. A clinical study to obtain Food and Drug Administration marketing clearance is under way, Corindus said.
By AuntMinnie.com staff writers
January 19, 2006
Copyright © 2006 AuntMinnie.com
![Representative example of a 16-year-old male patient with underlying X-linked adrenoleukodystrophy. (A, B) Paired anteroposterior (AP) chest radiograph and dual-energy x-ray absorptiometry (DXA) report shows lumbar spine (L1 through L4) areal bone mineral density (BMD). The DXA report was reformatted for anonymization and improved readability. The patient had low BMD (Z score ≤ −2.0). (C) Model (chest radiography [CXR]–BMD) output shows the predicted raw BMD and Z score in comparison with the DXA reference standard, together with interpretability analyses using Shapley additive explanations (SHAP) and gradient-weighted class activation maps. The patient was classified as having low BMD, consistent with the reference standard. AM = age-matched, DEXA = dual-energy x-ray absorptiometry, RM2 = room 2, SNUH = Seoul National University Hospital, YA = young adult.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/ai-children-bone-density.0snnf2EJjr.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
